TransMedics Sets 2026 Revenue Guidance at $764 Million to $774 Million Including PAD
TransMedics Group, Inc. raised its 2026 revenue guidance to $764M-$774M, up from $737M-$757M. The new range includes $14M from PAD Aviation. CEO Waleed Hassanein noted Q3 2026 was the company's strongest quarter for revenue and case volume.
How this was made

The 30-second read
Why it matters
The guidance lift suggests improved sales momentum and case volume growth.
Market read
First report of 2026 guidance, modestly better than prior range, may influence TMED price.
What to watch
Potential regulatory or reimbursement risks could offset the guidance lift.
Background
TransMedics Group provides organ perfusion technologies for transplant procedures.
Market effects
May lift sentiment for the broader organ transplant and medical device sector.
Limited to U.S. biotech investors.
Low, as the company is niche.
Counterpoint
Guidance increase is modest; market may have already priced in the upside.
Key entities
- ExecutiveWaleed Hassanein
President and CEO of TransMedics who announced the guidance.



